



Supplementary Material to Pourdjabbar et al. “A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study” (Thromb Haemost 2017; 117.1)




Suppl. Figure 1: P2Y12 Reactivity Unit at each specific time point – The difference in platelet function as assessed PRU between the two different strategies is demonstrated at each specific time point over the 72 hour study period. The values are expressed as the mean PRU at that specific time point. PRU = P2Y12 reactivity unit, NS = not significant.

Number of Patients with PRU > 208 at Various Time points



Suppl. Figure 2: Patients with HPR over the study period – The number of patients with HPR within each treatment group at each specific time point over the 72 hour time period. HPR = high on treatment platelet reactivity.

Number of Patients with PRU < 85 at Various Time points



Suppl. Figure 3: Patients with LPR over the study period – The number of patients with LPR within each treatment group at each specific time point over the 72 hour time period. LPR = low on treatment platelet reactivity.